Jemperli reimbursed as immunotherapy for endometrial cancer

Company will continue efforts to further expand reimbursement of the drug

GSK Korea holds a press conference celebrating the launch of its immunotherapy Jemperli’s reimbursement

Jemperli becomes the first immuno-oncology drug to be approved and granted reimbursement for endometrial cancer

GSK “has plans to expand indication”

GSK Korea holds a press conference celebrating the launch of its immunotherapy Jemperli’s reimbursement

A new immuno-oncology drug has been added to the sparse list of treatments available for endometrial cancer.

 

GSK Korea succeeded in obtaining insurance reimbursement for its Jemperli in a year since obtaining approval in Korea in December last year.

 

GSK Korea held a press conference on Sunday at Lotte Hotel Seoul to celebrate the launch of its immuno-oncology drug Jemperli (dostarlimab) in Korea.

 

The drug is a PD-1 inhibitor class immuno-oncology drug.

 

It was approved in Korea as a treatment for patients with recurrent or advanced deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) endometrial cancer that has progressed on or following prior systemic treatment with a platinum-containing chemotherapy regimen who are in December last year.

 

The drug was approved for reimbursement in 1 year since then.

 

Jemperli has been listed on the reimbursement list as of December 1.

 

Jemerli demonstrated efficacy in the GARNET trial that enrolled 143 patients with recurrent or advanced dMMR/MSI-H endometrial cancer.

 

After a median follow-up period of 27.6 months, Jemperli achieved an objective response rate (ORR) of 45.5%.

 

The complete response rate was 16.1%, and the partial response rate was 29.4%.

 

Among patients who showed treatment response, 93.3% and 83.7% of the patients showed continued treatment response at 12 months and 24 months, respectively.

 

Most of the reported adverse events were mild, and included diarrhea (16.3%), asthenia (15.7%), and fatigue (13.7%).

 

Jae-Weon Kim, Professor of Obstetrics and Gynecology at Seoul National University Hospital, said, “A limitation existed in the field due to lack of treatments available for use in case of recurrence after platinum-based chemotherapy.

 

Jemperli’s reimbursement holds significance as being the first immuno-oncology drug to be granted reimbursement in the field.” Jemperli attempts to expand its reimbursement as first-line therapy in endometrial cancer… an area that lacks treatment options At the conference, GSK also indicated the possibility of extending Jemperli’s marketing authorization to the first line in endometrial cancer.

 

Currently, the 5-year survival rate for recurrent endometrial cancer is reported to be less than 20%.

 

For recurrent patients who have failed first-line treatment, the survival rate falls further to less than 1 year.

 

The current first-line standard of care for endometrial cancer was the cytotoxic agent combination of paclitaxel and carboplatin.

 

Second-line treatment options are even more limited.

 

Old drugs such as paclitaxel, Avastin (bevacizumab), and docetaxel are being used as second-line treatment, but have not had a significant impact on improving survival.

 

Therefore, the company plans to expand Jemperli’s indication to the first line in endometrial cancer based on its clinical results while seeking approval for other cancers.

 

Yoo-jin Yang, managing director of GSK Korea’s Oncology BU, said, “We are working to secure more indications for Jemperli in other areas, in addition to endometrial cancer.

 

In endometrial cancer, we will work to receive approval for Jemperli as a first-line treatment."